Trial Profile
An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Jan 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 15 Nov 2023 Interim results assessing efficacy and safety of the LTE study were presented at the ACR Convergence 2023.
- 03 Jun 2023 Interim results reporting efficacy and safety of LTE study of secukinumab in patients with ERA and JPsA presented at the 24th Annual Congress of the European League Against Rheumatism